Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.-Reference-Cited by-同舟云学术

Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.

Published:1985-08-10 Issue:6492 Volume:291 Page:369-370
ISSN:0959-8138
Container-title:BMJ
language:en
Short-container-title:BMJ

Author:

Labrie F,Dupont A,Belanger A,Lachance R,Giguere M

Publisher

BMJ

Subject

General Earth and Planetary Sciences,General Environmental Science,General Engineering

Reference21 articles.

1. Studies of prostatic cancer. I. Effect ofcastration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate;C, I.Huggins; CV, Hodges;Cancer Res,1941

2. Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases;Nesbit, R.M.; Baum, W.C.,1950

3. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma;WP, Jr, Jordan; CE, Blackard; DP, Byar,1977

4. Cardiovascular complications to treatment of prostatic cancer with estramustine phosphate (Estracyt) or conventional oestrogen. A follow-up of 212 randomised patients;Hedlund, P.O.; Gustafsson, H.; Sjogren, S.;ScandJ Urol Nephrol,1980

5. Cardiovascular complications in the treatment of prostatic carcinoma;Glashan, R.W.; Robinson, M.R.G.,1981

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of switching therapy of luteinizing hormone–releasing hormone analogue for advanced prostate cancer;The Kaohsiung Journal of Medical Sciences;2016-11

2. Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study;Drugs - Real World Outcomes;2016-05-13

3. Structural Characterization of the Human Androgen Receptor Ligand-binding Domain Complexed with EM5744, a Rationally Designed Steroidal Ligand Bearing a Bulky Chain Directed toward Helix 12;Journal of Biological Chemistry;2007-10

4. Individualized Strategy for Dosing Luteinizing Hormone-Releasing Hormone Agonists for Androgen-Independent Prostate Cancer: Identification of Outcomes and Costs;Journal of Oncology Practice;2006-03-01

5. Individualized Strategy for Dosing Luteinizing Hormone–Releasing Hormone Agonists for Androgen-Independent Prostate Cancer: Identification of Outcomes and Costs;Journal of Oncology Practice;2006-03